Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. STOK
STOK logo

STOK Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Stoke Therapeutics Inc (STOK) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
31.000
1 Day change
2.45%
52 Week Range
40.220
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Stoke Therapeutics Inc (STOK) is not a strong buy for a beginner, long-term investor at this moment. While the stock has shown a slight upward price movement recently and has a positive MACD, there are no strong trading signals, significant catalysts, or financial data to support a compelling buy decision. Additionally, the lack of recent news, congress trading data, and valuation insights limits the ability to assess its long-term potential effectively.

Technical Analysis

The MACD histogram is positive at 0.24 and expanding, indicating a bullish trend. RSI is neutral at 64.578, and moving averages are converging, suggesting no clear directional momentum. Key resistance levels are at 31.068 and 31.872, while support levels are at 28.462 and 27.658.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
8

Positive Catalysts

  • The stock has shown a recent price increase of 2.45% in the regular market and 1.77% in post-market trading. The MACD is positive and expanding, which could indicate short-term bullish momentum.

Neutral/Negative Catalysts

  • No significant news, congress trading data, or valuation data is available. Hedge funds and insiders are neutral with no notable trading trends. Analyst ratings and price target changes are not provided, and the stock's historical volatility is relatively high at 41.91.

Financial Performance

No financial data is available for analysis, as the latest quarter's financials could not be retrieved.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes are available for Stoke Therapeutics Inc.

Wall Street analysts forecast STOK stock price to rise
9 Analyst Rating
Wall Street analysts forecast STOK stock price to rise
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 30.260
sliders
Low
25
Averages
35.75
High
50
Current: 30.260
sliders
Low
25
Averages
35.75
High
50
Canaccord
NULL -> Buy
maintain
$36 -> $60
AI Analysis
2026-03-20
Reason
Canaccord
Price Target
$36 -> $60
AI Analysis
2026-03-20
maintain
NULL -> Buy
Reason
Canaccord raised the firm's price target on Stoke Therapeutics to $60 from $36 and keeps a Buy rating on the shares. The firm believes consensus is low as the company reiterated its timeline that it expects to complete enrollment on its ongoing Phase 3 EMPEROR trial for zorevunersen for Dravet syndrome in 2Q26, with data in mid-2027. The reason for the target increase is based on the new net price of $600k/year for zorevunersen.
Wedbush
Outperform
upgrade
$36 -> $38
2026-03-18
Reason
Wedbush
Price Target
$36 -> $38
2026-03-18
upgrade
Outperform
Reason
Wedbush raised the firm's price target on Stoke Therapeutics to $38 from $36 and keeps an Outperform rating on the shares. The firm notes the company has released their 10-K filing and while no separate press release was issued, all key objectives remain on track for the company. Most important in the near term remains the enrollment completion for the Phase 3 EMPEROR study of zorevunersen in Dravet Syndrome. Additionally, the recent publication of zorevunersen clinical data in NEJM reinforces Wedbush's view that the company is assembling a compelling data package for the drug with benefits on both seizure and non-seizure manifestations of disease.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for STOK
Unlock Now

People Also Watch